# DiogenX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/diogenx

- Industry: Biotechnology
- Headquarters: Marseille, France
- Website: www.diogenx.com
- Total disclosed funding: $35M
- Latest round: Series A (May 10, 2023)
- Investors on record: 6

## About

DiogenX is a biotechnology company focused on developing innovative biologics for treating Type 1 Diabetes (T1D) through the regeneration of pancreatic beta cells, offering potential disease-modifying therapies.Founded in 2020 and headquartered in Marseille, France, DiogenX specializes in biologics aimed at treating Type 1 Diabetes. The company is co-founded by Benjamin Charles and Patrick Collombat. DiogenX has completed 2 deals, with its most recent funding round occurring on May 10, 2023, when it raised EUR 27.5 mn in a Series A round led by Boehringer Ingelheim Venture and Roche Venture. The company has not undergone significant pivots in its business strategy since its inception.DiogenX specializes in developing innovative biologics aimed at treating Type 1 Diabetes (T1D) through the regeneration of insulin-producing pancreatic beta cells. The company's lead program, DGX-01, utilizes a proprietary approach to modulate the Wnt/ß-catenin signaling pathway, aiming to restore pancreatic function and provide a disease-modifying therapy for T1D patients. DiogenX primarily serves the diabetes patient population globally, especially in regions with high T1D prevalence, including North America and Europe.DiogenX's revenue model is based on partnerships and collaborations with major pharmaceutical companies and research institutions in the biopharma sector. The company engages in B2B transactions, collaborating with investors and partners focused on advancing diabetes treatments. These transactions involve funding for research and development initiatives, with payments linked to milestone achievements in clinical development. In 2023, the company's EBITDA was EUR -4,810,752.20.In May 2023, DiogenX raised EUR 27.5 mn in Series A funding, which will be utilized to advance its lead drug candidate, DGX-01, towards clinical development in patients with Type 1 Diabetes (T1D). The company aims to expand its market presence, particularly targeting regions with significant T1D prevalence. Plans for future product launches include advancing DGX-01 through clinical trials, although specific release dates have not been disclosed.

## Funding rounds

- Series A, May 10, 2023, $30M — Omnes Capital, Boehringer Ingelheim Venture, Roche Venture Fund, Eli Lilly & Company, JDRF T1D Fund, AdBio Partners
- Seed, May 19, 2020, $4.9M — Boehringer Ingelheim Venture, JDRF T1D Fund, AdBio Partners

## Investors

- Boehringer Ingelheim Venture (https://capitalatlas.ai/funds/boehringer-ingelheim-venture) — Seed, Series A
- JDRF T1D Fund (https://capitalatlas.ai/funds/jdrf-t1d-fund) — Seed, Series A
- AdBio Partners (https://capitalatlas.ai/funds/adbio-partners) — Seed, Series A
- Omnes Capital (https://capitalatlas.ai/funds/omnes-capital) — Series A
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series A
- Eli Lilly & Company — Series A